1. Home
  2. WNEB vs LCTX Comparison

WNEB vs LCTX Comparison

Compare WNEB & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$12.58

Market Cap

259.2M

Sector

Finance

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.67

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
LCTX
Founded
1853
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.2M
407.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WNEB
LCTX
Price
$12.58
$1.67
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$11.00
$4.25
AVG Volume (30 Days)
55.0K
1.2M
Earning Date
01-27-2026
11-06-2025
Dividend Yield
2.22%
N/A
EPS Growth
27.15
N/A
EPS
0.66
N/A
Revenue
$79,080,000.00
$10,816,000.00
Revenue This Year
N/A
$6.32
Revenue Next Year
$7.48
$124.49
P/E Ratio
$19.24
N/A
Revenue Growth
9.08
24.05
52 Week Low
$7.63
$0.37
52 Week High
$13.95
$2.09

Technical Indicators

Market Signals
Indicator
WNEB
LCTX
Relative Strength Index (RSI) 46.14 46.95
Support Level $13.20 $1.58
Resistance Level $13.51 $1.77
Average True Range (ATR) 0.34 0.08
MACD -0.11 -0.01
Stochastic Oscillator 0.71 36.73

Price Performance

Historical Comparison
WNEB
LCTX

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: